Digital Edition

Ophthalmology Times: September/October 2026
Volume: 51
Issue: 5

Ophthalmology Times: July/August 2026
Volume: 51
Issue: 4

Ophthalmology Times: May/June 2026
Volume: 51
Issue: 3

Ophthalmology Times: March/April 2026
Volume: 51
Issue: 2

Ophthalmology Times: January/February 2026
Volume: 51
Issue: 1

Ophthalmology Times: November/December 2025
Volume: 50
Issue: 6

Ophthalmology Times: September/October 2025
Volume: 50
Issue: 5

Ophthalmology Times: July/August 2025
Volume: 50
Issue: 4

Ophthalmology Times: May/June 2025
Volume: 50
Issue: 3

Ophthalmology Times: March/April 2025
Volume: 50
Issue: 2

Ophthalmology Times: January/February 2025
Volume: 50
Issue: 1

Ophthalmology Times: December 2024
Volume: 49
Issue: 12

Ophthalmology Times: November 2024
Volume: 49
Issue: 11

Ophthalmology Times: October 2024
Volume: 49
Issue: 10

Ophthalmology Times: September 2024
Volume: 49
Issue: 9

Ophthalmology Times: August 2024
Volume: 49
Issue: 8

Ophthalmology Times: July 2024
Volume: 49
Issue: 7

Ophthalmology Times: June 2024
Volume: 49
Issue: 6

Ophthalmology Times: May 2024
Volume: 49
Issue: 5

Ophthalmology Times: April 2024
Volume: 49
Issue: 4

Ophthalmology Times: March 2024
Volume: 49
Issue: 3

Ophthalmology Times: February 2024
Volume: 49
Issue: 2

Ophthalmology Times: January 2024
Volume: 49
Issue: 1

Ophthalmology Times: December 2023
Volume: 48
Issue: 12

Ophthalmology Times: November 2023
Volume: 48
Issue: 11

Ophthalmology Times: October 2023
Volume: 48
Issue: 10

Ophthalmology Times: September 2023
Volume: 48
Issue: 9

Ophthalmology Times: August 2023
Volume: 48
Issue: 8

Ophthalmology Times: July 2023
Volume: 48
Issue: 7

Ophthalmology Times: June 2023
Volume: 48
Issue: 6
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
AAO 2026: Optogenetic gene therapy heads to phase 2 trial in geographic atrophy
2
AAO 2026: DAYBREAK shows tarcocimab and tabirafusp-ted noninferior to aflibercept in wet AMD
3
AAO 2026: BRUNELLO 1-year results for remigromig in DME
4
Slowing Stargardt: What a 36% reduction in lesion growth could mean for adolescent patients
5
